NK cell activation is one strategy to improve the immunotherapy of non-Hodgkin's lymphoma. So, we aimed to investigate expression of Natural killer cell activating receptor NKp44 in patients with diffuse large B-cell lymphoma (DLBCL) and its correlation with clinic pathological data. In this study, 30 new cases with DLBCL in addition to 20 healthy control were involved. All were submitted to full history, clinical examination, histopathology, Routine laboratory investigations including CBC, LDH, β2microgloubine and bone marrow examination. Cell culture of peripheral blood mononuclear cells and expression of CD56 and NKp44 by flowcytometry was done. We demonstrated increased NK cell populations (CD 56 + ve NKp44 –ve, CD 56 –veNKp44 + ve, total CD 56 + ve) and NKp44 MFI after in-vitro activation in both healthy control and DLBCL cases except for CD 56 + ve NKp44 + ve which significantly increased in patients not in healthy control (p = 0.005, 0.601) respectively. No significant difference between the DLBCL and healthy control regarding all NK cell populations without PHA stimulation. However, the culture with PHA in DLBCL showed significant increase in NK cell populations than the healthy control (CD 56 + ve NKp44 + ve 12.37 ± 7.52vs 6.80 ± 4.07, p = 0.008), (Total CD 56 + ve 18.80 ± 8.74vs 12.66 ± 5.17, p = 0.017), (MFI of NKp44 10.95 ± 6.18vs 5.58 ± 1.70, p = 0.001). Regarding the association with clinic pathologic features, increased expression of NKp44 was associated with lower values of LDH and earlier stages of DLBCL (p < 0.05). So, activating receptor NKp44 can be modulated by in-vitro activation, hence improvement of its function as an approach of immunotherapy of DLBCL.

NK细胞活化是改善非霍奇金淋巴瘤免疫治疗的一种策略。因此，我们旨在研究自然杀伤细胞激活受体NKp44在弥漫性大B细胞淋巴瘤（DLBCL）患者中的表达及其与临床病理数据的相关性。在这项研究中，除20名健康对照者外，还涉及30例新的DLBCL病例。所有患者均接受完整的病史，临床检查，组织病理学，常规实验室检查，包括CBC，LDH，β2微球蛋白和骨髓检查。通过流式细胞术完成了外周血单个核细胞的细胞培养以及CD56和NKp44的表达。我们证明了NK细胞数量增加（CD 56 + ve NKp44 –ve，CD 56 –veNKp44 + ve，在健康对照和DLBCL病例中，体外激活后体外激活后总CD 56 + ve）和NKp44 MFI除外，在健康对照以外的患者中CD 56 + ve NKp44 + ve分别显着增加（p = 0.005，0.601）。对于没有PHA刺激的所有NK细胞群体，DLBCL与健康对照组之间无显着差异。但是，在DLBCL中使用PHA的培养物显示NK细胞群体显着高于健康对照组（CD 56 + ve NKp44 + ve 12.37±7.52vs 6.80±4.07，p = 0.008），（CD 56 + ve 18.80±8.74vs总和12.66±5.17，p = 0.017），（NKp44的MFI为10.95±6.18vs 5.58±1.70，p = 0.001）。关于与临床病理特征的关系，NKp44的表达增加与LDH值较低和DLBCL的早期有关（p <0.05）。所以，